Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA) will deliver an oral presentation of Week 52 long-term follow up data for icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles on Dec 3-6, 2025. The oral talk (Abstract #0062COVALENT-111) is titled "Durable Glycemic and C-Peptide Improvements with Icovamenib, a Menin Inhibitor Targeting β-Cell Restoration in Insulin-Deficient Type 2 Diabetes" and is scheduled for Dec 5, 2025, 6:15 pm–7:45 pm PST. Biomea noted it is one of six oral presentations at the meeting and said poster and presentation materials will be available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – BMEA
In the Dec 2 session, BMEA declined 5.22%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | KOL presentation | Positive | -0.7% | KOL interview and WCIRDC presentation on menin inhibitors and icovamenib. |
| Dec 05 | Clinical results | Positive | +3.9% | COVALENT-111 data showing durable glycemic and C-peptide improvements at week 52. |
| Dec 01 | Conference presentation | Positive | -7.3% | Announcement of WCIRDC oral presentation for week 52 icovamenib follow-up data. |
| Dec 01 | Equity inducement | Neutral | -7.3% | Inducement stock option grant to a new employee under 2023 plan. |
| Nov 24 | Investor conferences | Neutral | +2.9% | Planned participation in early December investor healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News around icovamenib and conferences has produced mixed reactions, with some positive clinical updates aligning with gains and several communication-focused items seeing negative or muted moves.
Over the past few weeks, Biomea Fusion has focused investor attention on icovamenib and its diabetes pipeline. The company highlighted investor conference participation in early December 2025, announced this WCIRDC oral presentation on Dec 1, then shared detailed COVALENT‑111 results on Dec 5 and a KOL discussion on Dec 9. Alongside this, an inducement equity grant and prior financing activities appeared in filings. Today’s WCIRDC oral‑presentation news fits into this ongoing effort to showcase long‑term icovamenib data in insulin‑deficient type 2 diabetes.
Key Terms
c-peptide medical
menin inhibitor medical
β-cell medical
type 2 diabetes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 2025. The Congress showcases cutting-edge developments from both emerging investigators and world-renowned leaders.
“We are delighted to present our Week 52 long-term follow up data at WCIRDC, a meeting renowned for showcasing exciting advances in diabetes and metabolic research,” said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. “Being one of only six oral presentations this year speaks to the interest in icovamenib as a potential paradigm shift in the treatment of type 2 diabetes. Insulin-deficient diabetes remains an underserved population with limited therapeutic options, and icovamenib is potentially a novel treatment option for these patients.”
Oral Presentation Abstract #0062
COVALENT-111: Durable Glycemic and C-Peptide Improvements with Icovamenib, a Menin Inhibitor Targeting β-Cell Restoration in Insulin-Deficient Type 2 Diabetes
Presentation Time
Oral Presentation: December 5, 2025, from 6:15 pm – 7:45 pm PST
Please find a link here to our website where the poster and presentations will be available.
About Icovamenib
Icovamenib is an investigational, orally bioavailable, potent, and selective covalent inhibitor of menin. The proposed mechanism of action for icovamenib in diabetes is selective and partial inhibition of menin, a regulator of beta cell quantity and function, thereby enabling the proliferation, preservation, and reactivation of a patient’s own healthy, functional, insulin-producing beta cells. As the first non-chronic therapy for T2D, icovamenib could become an important addition to the diabetes treatment landscape once it has successfully completed its ongoing clinical studies.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at www.biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com
